Back to the main directory
Company Analysis / Equity
- APHRIA: Model update post Q2 results | BUY | CAD6.5 vs. CAD12.4 (+16%) by Bryan Garnier
- BASILEA PHARMACEUTICA: FY feedback: Derazantinib poised to become the most versatile FGFR inhibitor around | BUY | CHF95 vs. CHF78 (+59%) by Bryan Garnier
- EUROBIO SCIENTIFIC - Marquage CE test coronavirus Seegene (+) by MidCap Partners
- CAMPARI: Disappointing Q4 results and uninspiring 2020 guidance | NEUTRAL | EUR8.7(-2%) by Bryan Garnier
- ATOS: Unsurprising FY19 results, free cash flow and FY20 guidance | BUY - Top Picks | EUR107(+32%) by Bryan Garnier
- HBL_CY19 Results Review, (AKD, Off the Analyst's Desk, Feb 19, 2020) by AKD Securities Limited
- INDU: 1HFY20 Result Review, (AKD, Off the Analyst's Desk, Feb 19, 2020) by AKD Securities Limited
- UBL_CY19 Result Review, (AKD, Off the Analyst's Desk, Feb 19, 2020) by AKD Securities Limited
- Pixium Vision - Wrapping up 2019 with a solid financial position by Edison Investment Research
- Allied Minds - Federated moving towards commercialisation by Edison Investment Research
- Leclanché - Convertible loan from Yorkville Advisors by Edison Investment Research
- 6PM Call: Pennies shines by Viet Dragon Securities
- MOSL: Morning India (20/February/20): 1. Voices (Mixed commentary; short-term respite not visible yet!); 2. Hero MotoCorp (R&D ramp up to accelerate transformation) by Motilal Oswal
- FOCUS HOME INTERACTIVE - Saber : pas d’impact à CT et MT, à priori (+) by MidCap Partners
- Daily Market briefing - West African Regional Stock Exchange by Hudson & Cie
- Diversified Gas & Oil - Strong hedging programme supporting cash flows by Edison Investment Research
- NEXTEDIA - CA 2019: 24,4 M€, +8,6%, en ligne - Opinion Achat - Objectif: 1,06 € (vs 1,11€) - Potentiel:+46% by GreenSome Finance
- Research Note - Eyemaxx Real Estate AG - 20.02.20 by GBC AG
- XILAM - 2019 Revenue (-) Short Term Frustrations by MidCap Partners
- ALTEN BUY | EUR123 FY19 meeting feedback: the picture still looks good by Bryan Garnier
- BOUYGUES NEUTRAL | EUR39 Exceptional dividend alongside good FY 2019 results by Bryan Garnier
- ACCOR BUY | EUR47 FY results: Sustained as expected. Health crisis hard to measure by Bryan Garnier
- GENMAB BUY | DKK1900 vs. DKK1700 Higher-than.expected 2020 OPEX guidance could be good entry point by Bryan Garnier
- SCHNEIDER ELECTRIC BUY | Under review Solid Q4, positive outlook and reassuring comments on China by Bryan Garnier
- Research Comment - Media and Games Invest plc - 20.02.20 by GBC AG